Seattle Genetics (SGEN) Misses Q2 EPS by 12c, Offers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Seattle Genetics Reports Second Quarter 2015 Financial Results
July 30, 2015 4:02 PM EDT-Total Second Quarter 2015 Revenues of $77.1 Million, Including Record $55.1 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-ADCETRIS 2015 Net Sales Guidance Increased to a Range of $210 Million to $220 Million-
-Potential ADCETRIS Label Expansion through AETHERA Supplemental Biologics License Application (BLA) Currently Under FDA Priority Review; PDUFA Action Date August 18, 2015-
-Additional Clinical Data from Multiple Pipeline Programs Expected In Next Six to Nine Months, Including SGN-CD33A for Acute Myeloid Leukemia-
-Conference Call Today at 4:30 p.m. ET-... More
